On the Empowered Patient Podcast, Avalon Vice President of Product Dr. Julie Schulz, MD, MPH, sheds light on how advanced lab data integration is reshaping the use of GLP-1 drugs in treating cardiometabolic conditions. With lab values like hemoglobin A1C and lipid panels, providers can pinpoint patients who stand to benefit most, improving outcomes for diabetes, obesity, and cardiovascular risk management.

Dr. Schulz emphasized the importance of using real-time lab insights to streamline decisions, eliminate treatment delays, and address inequities in care access. The result? A faster, more targeted approach that maximizes the impact of GLP-1 therapies.

Listen in below: